Cordyceps

Metadata

Approved Indications

European Regulatory Bodies

Cordyceps has not been assessed by any of the three major European phytotherapy regulatory bodies:

• Commission E (Germany): No monograph exists. Cordyceps was never part of the European herbal tradition evaluated by Commission E.
• ESCOP: No monograph. Not within the scope of European scientific cooperative assessment.
• EMA/HMPC: No assessment report or monograph. C. militaris mycelium has been submitted under the EU Novel Food Regulation (EC) No 258/97, with some authorized products on the market.

This is not a negative assessment — these bodies simply never evaluated it, as it originates from the Chinese (TCM) and Tibetan medical traditions rather than the European phytotherapy tradition.

Chinese Pharmacopoeia

• Listed: Yes. Dong Chong Xia Cao (Cordyceps) is an official drug in the Chinese Pharmacopoeia (2020 edition).
• Official species: Ophiocordyceps sinensis (the wild caterpillar-fungus complex).
• Traditional indications: Tonifying the kidney and supplementing the lung; used for kidney deficiency with impotence, seminal emission, aching of the lumbar region and knees, chronic cough with dyspnea from lung deficiency, and hemoptysis due to consumptive disease.

Tibetan and Nepali Traditional Medicine

• Tibetan name: Yartsa gunbu (literally “summer grass, winter worm”).
• Traditional use: Used for centuries in Tibetan and Nepali highland medicine as a general tonic and aphrodisiac. Collected at altitudes of 3,000-5,000 m on the Tibetan Plateau and Himalayan regions.
• Economic significance: Wild-harvested O. sinensis represents a major cash income source for Tibetan and Nepali highland communities, sometimes exceeding 50% of household income.

United States

• Dietary supplement: Widely sold as a dietary supplement under DSHEA. Cs-4 mycelium and cultivated C. militaris fruiting body products are the predominant commercial forms.
• No GRAS determination specific to cordyceps extracts at the time of writing.

European Union

• Novel food status: C. militaris mycelium biomass has received novel food authorization in some EU member states. Whole fruiting body products may require separate authorization depending on the specific preparation and member state.

Conditions Treated

Primary (Moderate Evidence)

• Physical performance and endurance — Multiple small RCTs demonstrate improvements in VO2 max and time-to-exhaustion in both elderly and younger adult populations. Proposed mechanism involves enhanced mitochondrial ATP production and improved oxygen utilization via cordycepin/adenosine signaling.
• Fatigue reduction — Both traditional use and clinical trials support anti-fatigue effects, particularly in elderly or debilitated individuals. Cs-4 supplementation has shown significant improvements in fatigue scores in controlled trials.
• Immune modulation — Beta-glucan polysaccharides stimulate innate immune function (macrophage activation, NK cell activity); paradoxically, cordycepin also demonstrates anti-inflammatory properties. Net effect is immunomodulatory rather than purely immunostimulant.

Secondary (Preliminary Evidence)

• Respiratory function — Traditional TCM indication for lung deficiency; limited clinical evidence suggests improved respiratory function in chronic obstructive pulmonary disease (COPD) and asthma patients as adjunctive therapy.
• Sexual function — Traditional aphrodisiac use supported by small clinical studies showing improved libido and sexual function, particularly in elderly men. Mechanism may involve testosterone modulation and nitric oxide enhancement.
• Renal support — Zhu et al. (1998) meta-analysis of Chinese clinical trials found evidence for improved renal function markers in chronic kidney disease patients receiving Cordyceps as adjunctive therapy.

Emerging/Preclinical

• Anti-tumor activity — Cordycepin demonstrates broad anti-proliferative activity in vitro across multiple cancer cell lines (inhibition of mRNA polyadenylation, induction of apoptosis, AMPK activation). No clinical trial evidence for anti-cancer efficacy in humans.
• Anti-aging and longevity — Preclinical evidence for extension of lifespan in model organisms (Drosophila, C. elegans); proposed mechanisms include antioxidant activity, mitochondrial protection, and telomere maintenance. Clinical relevance is unestablished.
• Blood glucose regulation — Animal studies and small human pilot trials suggest hypoglycemic activity, potentially through enhanced insulin sensitivity and modulation of hepatic glucose metabolism. Insufficient clinical evidence.

Mechanism of Action

Primary Mechanisms

1. Cordycepin as adenosine analog: Cordycepin (3’-deoxyadenosine) is a structural analog of adenosine, differing only by the absence of a hydroxyl group at the 3’ position of the ribose ring. It interacts with adenosine receptors (A1, A2A, A2B, A3) and adenosine metabolic pathways. A1 receptor agonism may mediate sedative and cardioprotective effects; A2A agonism contributes to vasodilation and anti-inflammatory activity; A3 receptor modulation has been linked to anti-cancer effects in preclinical models. Cordycepin is also incorporated into RNA, causing premature chain termination and inhibiting mRNA polyadenylation — a mechanism underlying its anti-proliferative activity.

2. Mitochondrial bioenergetics enhancement: Cordyceps extracts and cordycepin have been shown to upregulate mitochondrial biogenesis via AMPK/PGC-1alpha signaling, increase cellular ATP/ADP ratios, and enhance oxidative phosphorylation efficiency. This mechanism is consistent with observed improvements in aerobic exercise performance and resistance to fatigue.

3. Beta-glucan immune stimulation: Cordyceps polysaccharides, primarily beta-(1→3)-D-glucans with (1→6) branching, activate innate immune cells through dectin-1 and toll-like receptor 2 (TLR-2) signaling. This stimulates macrophage phagocytosis, increases NK cell cytotoxicity, and promotes dendritic cell maturation. The immunomodulatory polysaccharide profile of cultivated C. militaris is comparable to wild O. sinensis.

Secondary Mechanisms

4. Anti-inflammatory activity (NF-kB inhibition): Cordycepin inhibits NF-kB nuclear translocation and downstream pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6). This occurs partly through adenosine A2A receptor activation and partly through direct inhibition of IKK phosphorylation.

5. Antioxidant activity: Cordyceps extracts scavenge reactive oxygen species and upregulate endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) via Nrf2 pathway activation. Ergosterol and polyphenolic constituents contribute to direct radical scavenging.

6. Adenosine-mediated vasodilation and oxygen utilization: Adenosine and cordycepin promote vasodilation through A2A and A2B receptor-mediated smooth muscle relaxation, improving peripheral blood flow and tissue oxygenation. This mechanism, combined with mitochondrial enhancement, provides a coherent pharmacological basis for the observed exercise performance improvements.

Key Pharmacological Note

Cordycepin has a short in vivo half-life due to rapid deamination by adenosine deaminase (ADA). Co-administration with ADA inhibitors (such as pentostatin) dramatically extends cordycepin half-life and potency in preclinical models — this is relevant primarily to oncology research rather than supplement use. The bioavailability of cordycepin from whole extract preparations (which contain multiple constituents) may differ from isolated compound studies.

Clinical Evidence Summary

Clinical evidence for cordyceps is drawn from trials using Cs-4 mycelium preparations, cultivated C. militaris fruiting body extracts, and traditional O. sinensis. While multiple RCTs exist, most are small, and several influential early studies were conducted in China without independent replication.

Exercise Performance and VO2 Max

Fatigue and General Vitality

Renal Function

Important Historical Context

In 1993, the Chinese women’s Olympic distance running team shattered multiple world records. Their coach, Ma Junren, attributed the performances to a regimen that included Cordyceps supplementation (among other factors including intensive training). These claims generated worldwide commercial interest in Cordyceps but were never independently verified in controlled studies. Several athletes from this program later tested positive for banned substances. The episode illustrates the importance of distinguishing anecdotal claims from controlled trial evidence.

Evidence Limitations

• Most positive RCTs have small sample sizes (n=20-28 for the exercise performance studies).
• The Zhu et al. (1998) meta-analysis compiled Chinese-language trials of variable methodological quality that have not been independently replicated.
• Exercise performance results are inconsistent: Parcell et al. (2004) found no benefit in trained cyclists, suggesting effects may be more pronounced in untrained or elderly populations.
• Heterogeneity of preparations (Cs-4 mycelium, C. militaris fruiting body, various extracts) makes cross-study comparison difficult.
• Publication bias is a concern, particularly for Chinese-language trials.
• No large (n>100), multi-center, independently funded RCTs have been published.

Safety Profile

General Assessment

Cordyceps preparations (Cs-4 mycelium, cultivated C. militaris) appear to be generally well-tolerated in published clinical trials at standard doses. Traditional use of O. sinensis spans over 1,500 years in TCM and Tibetan medicine. However, systematic long-term safety data from large controlled trials is lacking.

Contraindications

• Pregnancy: Contraindicated due to insufficient safety data. No human studies in pregnant women. Some preclinical evidence suggests potential effects on sex hormones.
• Lactation: Insufficient data. Avoid until safety is established.
• Autoimmune disease: Theoretical concern that immunostimulatory beta-glucans could exacerbate autoimmune conditions (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis). Use with caution; clinical evidence for this interaction is lacking but the theoretical concern is plausible.
• Pre-surgical: Discontinue at least 2 weeks before surgery due to potential antiplatelet activity and interaction with anesthesia.

Drug Interactions

• Anticoagulants and antiplatelets (warfarin, heparin, aspirin, clopidogrel): Cordycepin has demonstrated antiplatelet and mild anticoagulant activity in vitro and in animal models. Theoretical increased bleeding risk with concurrent anticoagulant therapy. Monitor INR closely if co-administered with warfarin.
• Immunosuppressants (cyclosporine, tacrolimus, cyclophosphamide): Cordyceps beta-glucans may counteract immunosuppressive therapy by stimulating immune function. Avoid concurrent use in transplant patients or those on immunosuppressive regimens without physician supervision.
• Theophylline: Cordycepin, as an adenosine analog, may interact with adenosine receptor signaling pathways also affected by theophylline (an adenosine receptor antagonist). Theoretical antagonistic interaction on bronchodilatory and cardiac effects. Clinical significance is uncertain but warrants caution.
• Antidiabetic medications: Cordyceps may have additive hypoglycemic effects. Monitor blood glucose if co-administered with insulin or oral hypoglycemics.
• CYP450 substrates: Limited in vitro data suggest potential inhibition of CYP3A4 and CYP2D6 by cordyceps extracts. Clinical significance is uncertain.

Side Effects (at recommended doses)

• Common: Generally well-tolerated. Mild GI discomfort (nausea, diarrhea, dry mouth) reported infrequently.
• Uncommon: Allergic reactions in individuals with mold or fungal sensitivities.
• Rare: Case reports of lead poisoning from contaminated wild-harvested O. sinensis products originating from the Tibetan Plateau.

Contamination and Quality Concerns

• Wild-harvested O. sinensis: Due to the extreme value of wild Cordyceps (exceeding the price of gold by weight), adulteration and contamination are significant concerns. Heavy metal contamination (lead, arsenic, cadmium) has been documented in specimens collected from mining-adjacent areas of the Tibetan Plateau. Lead-filled specimens to increase weight for sale have been reported.
• Cultivated C. militaris: Generally free of heavy metal concerns when produced under GMP conditions, but third-party testing (heavy metals, arsenic, microbial contamination) is advisable.
• Species verification: DNA authentication is recommended, as substitution of cheaper fungal species for genuine Cordyceps products is widespread in the global market.

Clinical Dosage

Cs-4 Mycelium (Fermented O. sinensis Mycelium)

• Standard dose: 3-4.5 g/day of Cs-4 mycelium powder, typically divided into 2-3 doses
• This is the most clinically studied preparation (used in Chen et al. 2010, Yi et al. 2004, Parcell et al. 2004)
• Standardization: Typically standardized to adenosine content (>0.14%) and/or mannitol content (>7%)

Cultivated C. militaris Fruiting Body Extract

• Standard dose: 1-3 g/day of dried fruiting body powder or equivalent extract
• Cordycepin content: Cultivated C. militaris typically contains 3-8 mg/g cordycepin (significantly higher than wild O. sinensis)
• Extraction method: Hot-water extraction captures polysaccharides; dual extraction (hot water + ethanol) captures both polysaccharides and cordycepin

Cordycepin-Standardized Extracts

• Dose varies by product depending on cordycepin concentration
• Typical range: 200-1,000 mg of extract standardized to a specified cordycepin content
• Note: Standardization to cordycepin is relatively new and dosing is largely empirical

Traditional O. sinensis (Decoction)

• Traditional dose: 3-9 g/day in decoction
• Rarely used today due to extreme cost (USD $20,000-100,000/kg) and ecological unsustainability
• Chinese Pharmacopoeia dose: 3-9 g

Sources

• Chen S, Li Z, Krochmal R, Abrazado M, Kim W, Cooper CB. Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial. J Altern Complement Med. 2010;16(5):585-590
• Hirsch KR, Smith-Ryan AE, Roelofs EJ, Trexler ET, Mock MG. Cordyceps militaris improves tolerance to high-intensity exercise after acute and chronic supplementation. J Diet Suppl. 2017;14(1):42-53
• Yi X, Xi-zhen H, Jia-shi Z. Randomized double-blind placebo-controlled clinical trial and assessment of fermentation product of Cordyceps sinensis (Cs-4) in enhancing aerobic capacity and respiratory function of the healthy elderly volunteers. Chin J Integr Med. 2004;10(3):187-192
• Parcell AC, Smith JM, Schulthies SS, Myrer JW, Fellingham G. Cordyceps sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. Int J Sport Nutr Exerc Metab. 2004;14(2):236-242
• Zhu JS, Halpern GM, Jones K. The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis Part I and Part II. J Altern Complement Med. 1998;4(3):289-303 and 4(4):429-457
• Song J, Wang Y, Teng M, et al. Cordyceps militaris fruit body extract ameliorates membranous glomerulonephritis by attenuating oxidative stress and renal inflammation. Food Chem Toxicol. 2015;76:76-83
• Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to cordycepin. 3 Biotech. 2014;4(1):1-12
• Cunningham KG, Manson W, Spring FS, Hutchinson SA. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.) Link. Nature. 1950;166(4231):949
• Paterson RRM. Cordyceps — a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry. 2008;69(7):1469-1495
• Das SK, Masuda M, Sakurai A, Sakakibara M. Medicinal uses of the mushroom Cordyceps militaris: current state and prospects. Fitoterapia. 2010;81(8):961-968
• Shashidhar MG, Giridhar P, Udaya Sankar K, Manohar B. Bioactive principles from Cordyceps sinensis: a review. J Funct Foods. 2013;5(3):1013-1030
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition
• Winkler D. Yartsa Gunbu (Cordyceps sinensis) and the fungal commodification of Tibet’s rural economy. Econ Bot. 2008;62(3):291-305

Connections

• Compare with other adaptogenic and performance-enhancing fungi/herbs: reishi (immune modulation, beta-glucans), astragalus (immune tonic, traditional Chinese qi tonic), rhodiola (anti-fatigue, exercise performance), eleuthero (adaptogenic endurance support)
• The adenosine analog mechanism (cordycepin) is pharmacologically distinct from most herbal adaptogens and represents a unique bioactive profile among medicinal fungi
• Cordyceps beta-glucan immunomodulation parallels that of reishi (Ganoderma lucidum), turkey tail (Trametes versicolor), and maitake (Grifola frondosa)
• Contrast with European-tradition adaptogens: ashwagandha, rhodiola, and eleuthero operate through different primary mechanisms (HPA axis modulation, monoamine modulation) compared to cordycepin’s adenosine receptor pharmacology
• The ecological and economic dimensions of wild O. sinensis harvesting on the Tibetan Plateau represent one of the most significant conservation challenges in medicinal natural products